Luis J Espinoza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3254815/publications.pdf

Version: 2024-02-01

304743 276875 103 1,952 22 41 h-index citations g-index papers 106 106 106 3573 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget, 2016, 7, 52517-52529.	1.8	309
2	A Genetic Variant in the IL-17 Promoter Is Functionally Associated with Acute Graft-Versus-Host Disease after Unrelated Bone Marrow Transplantation. PLoS ONE, 2011, 6, e26229.	2.5	173
3	Resveratrol Induces Cell Cycle Arrest and Apoptosis in Malignant NK Cells via JAK2/STAT3 Pathway Inhibition. PLoS ONE, 2013, 8, e55183.	2.5	83
4	Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions. Haematologica, 2012, 97, 1295-1303.	3.5	82
5	Gastric microbiota: An emerging player in Helicobacter pylori -induced gastric malignancies. Cancer Letters, 2018, 414, 147-152.	7.2	72
6	Mycophenolic Acid Inhibits Natural Killer Cell Proliferation and Cytotoxic Function: A Possible Disadvantage of Including Mycophenolate Mofetil in the Graft-Versus-Host Disease Prophylaxis Regimen. Biology of Blood and Marrow Transplantation, 2011, 17, 205-213.	2.0	61
7	NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica, 2009, 94, 1427-1434.	3.5	54
8	A functional polymorphism in the NKG2D gene modulates NK-cell cytotoxicity and is associated with susceptibility to Human Papilloma Virus-related cancers. Scientific Reports, 2016, 6, 39231.	3.3	52
9	The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	4.0	52
10	New Insights on the Pathogenesis of Takayasu Arteritis: Revisiting the Microbial Theory. Pathogens, 2018, 7, 73.	2.8	49
11	Resveratrol Prevents EBV Transformation and Inhibits the Outgrowth of EBV-Immortalized Human B Cells. PLoS ONE, 2012, 7, e51306.	2.5	46
12	Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cellâ€mediated cytolysis. Cancer Science, 2010, 101, 609-615.	3.9	41
13	The Host-Microbe Interplay in Human Papillomavirus-Induced Carcinogenesis. Microorganisms, 2019, 7, 199.	3.6	37
14	Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia Stimulate Peripheral Blood Mononuclear Cells to Secrete TNF- \hat{l} ± and IFN- \hat{l} 3. Journal of Immunology, 2009, 182, 703-710.	0.8	36
15	Resveratrol, a Natural Antioxidant From Grapes and Red Wines, Prevents EBV-Associated Lymphoproliferation and Transformation through Inducing Apoptosis. Blood, 2010, 116, 2543-2543.	1.4	31
16	Epstein–Barr Virus and Helicobacter Pylori Co-Infection in Non-Malignant Gastroduodenal Disorders. Pathogens, 2020, 9, 104.	2.8	30
17	Ataxia–telangiectasia mutated kinaseâ€mediated upregulation of <scp>NKG</scp> 2 <scp>D</scp> ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility. Cancer Science, 2013, 104, 657-662.	3.9	29
18	Sensing Bacterial-Induced DNA Damaging Effects via Natural Killer Group 2 Member D Immune Receptor: From Dysbiosis to Autoimmunity and Carcinogenesis. Frontiers in Immunology, 2018, 9, 52.	4.8	28

#	Article	IF	Citations
19	Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. Blood Advances, 2018, 2, 390-400.	5.2	27
20	Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis. Journal of Biomedical Science, 2019, 26, 45.	7.0	27
21	The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia. Cancer Letters, 2017, 400, 127-136.	7.2	25
22	Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells. Cells, 2019, 8, 226.	4.1	25
23	Artificial Intelligence Tools for Refining Lung Cancer Screening. Journal of Clinical Medicine, 2020, 9, 3860.	2.4	24
24	Emerging superbugs: The threat of Carbapenem Resistant Enterobacteriaceae. AIMS Microbiology, 2020, 7, 176-182.	2.2	24
25	A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT. Bone Marrow Transplantation, 2011, 46, 1455-1463.	2.4	23
26	Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. Molecular Nutrition and Food Research, 2015, 59, 2143-2154.	3.3	23
27	Autoantibodies specific to hnRNP K: a new diagnostic marker for immune pathophysiology in aplastic anemia. Annals of Hematology, 2010, 89, 1255-1263.	1.8	22
28	Immunomodulatory and Metabolic Changes after Gnetin-C Supplementation in Humans. Nutrients, 2019, 11, 1403.	4.1	22
29	Gnetin and other resveratrol oligomers with cancer chemopreventive potential. Annals of the New York Academy of Sciences, 2017, 1403, 5-14.	3.8	21
30	Elevated Monocyte to Lymphocyte Ratio and Increased Mortality among Patients with Chronic Kidney Disease Hospitalized for COVID-19. Journal of Personalized Medicine, 2021, 11, 224.	2.5	20
31	Paraptosis Cell Death Induction by the Thiamine Analog Benfotiamine in Leukemia Cells. PLoS ONE, 2015, 10, e0120709.	2.5	19
32	Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. International Journal of Hematology, 2017, 106, 691-703.	1.6	19
33	Machine learning for tackling microbiota data and infection complications in immunocompromised patients with cancer. Journal of Internal Medicine, 2018, 284, 189-192.	6.0	19
34	Rationale for assessing the therapeutic potential of resveratrol in hematological malignancies. Blood Reviews, 2019, 33, 43-52.	5.7	18
35	Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia. Annals of Hematology, 2016, 95, 771-781.	1.8	17
36	An altered gut microbiota may trigger autoimmune-mediated acquired bone marrow failure syndromes. Clinical Immunology, 2016, 171, 62-64.	3.2	16

#	Article	IF	Citations
37	Malaria Resurgence in the Americas: An Underestimated Threat. Pathogens, 2019, 8, 11.	2.8	16
38	Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V. Nature Communications, 2020, 11, 4147.	12.8	15
39	A single-nucleotide polymorphism of the $Fc\hat{l}^3$ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. Bone Marrow Transplantation, 2011, 46, 238-243.	2.4	14
40	The recipient CXCL10 +1642C> G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation. Clinical Immunology, 2013, 146, 104-111.	3.2	14
41	Genetic Variants of Human Granzyme B Predict Transplant Outcomes after HLA Matched Unrelated Bone Marrow Transplantation for Myeloid Malignancies. PLoS ONE, 2011, 6, e23827.	2.5	13
42	Microbe-Induced Inflammatory Signals Triggering Acquired Bone Marrow Failure Syndromes. Frontiers in Immunology, 2017, 8, 186.	4.8	13
43	Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: A systematic review. Journal of Infection, 2022, 84, 749-759.	3.3	13
44	Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-Â through an ERK1/2-dependent pathway. International Immunology, 2009, 21, 913-923.	4.0	12
45	Infection Complications in Hematopoietic Stem Cells Transplant Recipients: Do Genetics Really Matter?. Frontiers in Microbiology, 2018, 9, 2317.	3.5	12
46	Genetic Predisposition to Persistent Human Papillomavirus-Infection and Virus-Induced Cancers. Microorganisms, 2021, 9, 2092.	3.6	11
47	Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia. Haematologica, 2019, 104, e447-e450.	3.5	10
48	Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma. Blood, 2015, 126, 4244-4244.	1.4	10
49	Donor Heme Oxygenase-1 Promoter Gene Polymorphism Predicts Survival after Unrelated Bone Marrow Transplantation for High-Risk Patients. Cancers, 2020, 12, 424.	3.7	9
50	Resveratrol Enhances NKG2D-Mediated Cytotoxicity Against Leukemia Cells by Upregulating Both NKG2D Receptor on NK Cells As Well As NKG2D Ligands on Target Cells,. Blood, 2011, 118, 3236-3236.	1.4	9
51	The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-β. Leukemia, 2022, 36, 847-855.	7.2	9
52	Recipient PTPN22 â^'1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2013, 19, 240-246.	2.0	8
53	A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. International Journal of Hematology, 2015, 102, 460-470.	1.6	8
54	Recipient ADAMTS13 Single-Nucleotide Polymorphism Predicts Relapse after Unrelated Bone Marrow Transplantation for Hematologic Malignancy. International Journal of Molecular Sciences, 2019, 20, 214.	4.1	7

#	Article	IF	CITATIONS
55	Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. Leukemia Research Reports, 2020, 14, 100219.	0.4	6
56	<i>Toll-like receptor</i> genetic variations in bone marrow transplantation. Oncotarget, 2017, 8, 45670-45686.	1.8	6
57	The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. Transplant Immunology, 2017, 42, 34-39.	1.2	5
58	Disease modeling of bone marrow failure syndromes using iPSC-derived hematopoietic stem progenitor cells. Experimental Hematology, 2019, 71, 32-42.	0.4	5
59	Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality. Frontiers in Immunology, 2018, 9, 3031.	4.8	5
60	Tumourâ€immune microenvironment in duodenalâ€type follicular lymphoma. British Journal of Haematology, 2020, 191, 243-252.	2.5	5
61	Donor UNC-93 Homolog B1 genetic polymorphism predicts survival outcomes after unrelated bone marrow transplantation. Genes and Immunity, 2021, 22, 35-43.	4.1	5
62	Genetic variants in NKG2D axis and susceptibility to Epstein–Barr virus-induced nasopharyngeal carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 713-723.	2.5	5
63	The Impact of NLRP3 Activation on Hematopoietic Stem Cell Transplantation. International Journal of Molecular Sciences, 2021, 22, 11845.	4.1	5
64	Decreased expression of Tâ€eellâ€associated immune markers predicts poor prognosis in patients with follicular lymphoma. Cancer Science, 2021, , .	3.9	5
65	The Predominance of Klebsiella aerogenes among Carbapenem-Resistant Enterobacteriaceae Infections in Japan. Pathogens, 2022, 11, 722.	2.8	5
66	Induced pluripotent stem cell technology: A window for studying the pathogenesis of acquired aplastic anemia and possible applications. Experimental Hematology, 2017, 49, 9-18.	0.4	4
67	Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia. Internal Medicine, 2018, 57, 1445-1453.	0.7	4
68	Clonal hematopoiesis by SLIT1-mutated hematopoietic stem cells due to a breakdown of the autocrine loop involving Slit1 in acquired aplastic anemia. Leukemia, 2019, 33, 2732-2766.	7.2	4
69	Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy. Viruses, 2020, 12, 416.	3.3	4
70	A Sequence Variation in the Promoter Region of PTPN22 Gene Predicts Relapse After HLA-Fully-Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies. Blood, 2011, 118, 3088-3088.	1.4	4
71	Toll - like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies. Transplant Immunology, 2016, 38, 60-66.	1.2	3
72	Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. International Journal of Hematology, 2021, 114, 205-216.	1.6	3

#	Article	IF	CITATIONS
73	Generation of Ips Cell-Derived Hematopoietic Progenitor Cells from Patients with Acquired Aplastic Anemia Harboring Copy Number Neutral Loss of Heterozygosity of the Short Arm of Chromosome 6. Blood, 2015, 126, 2415-2415.	1.4	2
74	Resistance of KIR Ligand–Missing Leukocytes to NK Cells In Vivo in Patients with Acquired Aplastic Anemia. ImmunoHorizons, 2020, 4, 430-441.	1.8	2
75	Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. Cancers, 2018, 10, 304.	3.7	2
76	Interleukinâ€17â€producing angioimmunoblastic Tâ€cell lymphoma with Evans syndrome. British Journal of Haematology, 2019, 184, 122-122.	2.5	1
77	Antidiuretic hormone―and interleukinâ€6â€producing angioimmunoblastic Tâ€cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion. British Journal of Haematology, 2019, 184, 121-121.	2.5	1
78	CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence. International Journal of Hematology, 2022, 115, 336-349.	1.6	1
79	Epstein–Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation. Journal of Clinical Virology, 2016, 80, 82-86.	3.1	O
80	Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia. Leukemia and Lymphoma, 2021, 62, 507-509.	1.3	0
81	Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation. Leukemia Research Reports, 2021, 15, 100256.	0.4	O
82	Autoantibodies Specific to hnRNP K: A New Diagnostic Marker for Immune Pathophysiology in Bone Marrow Failure Syndromes Blood, 2008, 112, 2042-2042.	1.4	0
83	The Fcî³Rllla Polymorphism Correlates with Chronic Graft-Versus-Host Disease and Treatment Related Mortality Blood, 2008, 112, 2237-2237.	1.4	0
84	Identification of a Novel Auto-Antibody Highly Prevalent in Patients with Hepatitis-Associated and Idiopathic Aplastic Anemia Blood, 2009, 114, 3200-3200.	1.4	O
85	Significant Impact of IL-17A Gene Polymorphism On Transplant Outcomes After HLA-Fully-Matched Unrelated Bone Marrow Transplantation Blood, 2009, 114, 2305-2305.	1.4	0
86	Evidence of Common Mechanisms Underlying the Survival Advantage of the PIG-A mutant and 13q-Hematopoietic Stem Cell Clones In Patients with Immune-Mediated Bone Marrow Failure. Blood, 2010, 116, 4429-4429.	1.4	0
87	A Functional Variation In the NKG2D Gene Regulates NKG2D Receptor Expression and Is Associated with Better Transplant Outcomes After Fully-HLA-Matched Unrelated Bone Marrow Transplantation. Blood, 2010, 116, 221-221.	1.4	0
88	A Minor Genetic Variation In the Granzyme B Gene Predicts Relapse After HLA-Fully-Matched Unrelated Bone Marrow Transplantation for Hematologic Malignancies. Blood, 2010, 116, 681-681.	1.4	0
89	Role of Moesin in Murine Hematopoiesis. Blood, 2011, 118, 1338-1338.	1.4	0
90	The Association of a Single Nucleotide Polymorphism in the Chemokine CXCL10 Gene with Transplant Outcomes After HLA-Matched Unrelated Bone Marrow Transplantation for Low Risk Hematologic Malignancies. Blood, 2011, 118, 2048-2048.	1.4	0

#	Article	IF	CITATIONS
91	A Single Nucleotide Polymorphism in the NLRP3 Gene Is Associated with Acute Graft-Versus-Host Disease After HLA-Matched Unrelated Bone Marrow Transplantation,. Blood, 2011, 118, 4073-4073.	1.4	0
92	CD109 Deficiency Induces Preferential Proliferation of the Piga Mutant Leukemia Cell Line TF-1 in the Presence of TGF-1 ² . Blood, 2012, 120, 4399-4399.	1.4	0
93	Association of Functional Single Nucleotide Variation in the NLRP3 Gene with Survival Outcomes After Unrelated Bone Marrow Transplantation Blood, 2012, 120, 3140-3140.	1.4	0
94	Resveratrol Inhibits Myeloid Leukemia Cell Lines With JAK2V617F Via Both Inactivation Of The JAK/STAT Pathway and Upregulation Of The ERK Pathway. Blood, 2013, 122, 3854-3854.	1.4	0
95	A Profound Decrease in FoxP3+Helios+CD4+ T Cells in a Subset of Patients with Acquired Aplastic Anemia and Pure Red Cell Aplasia: A Common Mechanism Underlying a Dependency on Cyclosporine. Blood, 2014, 124, 4384-4384.	1.4	0
96	The Effects of the Repeated Administration of Resveratrol Monomer and Resveratrol Dimer on Circulating Immune Cells in Healthy Individuals. Blood, 2014, 124, 4141-4141.	1.4	0
97	Resistance of Hematopoietic Stem Cells Lacking the KIR Ligand to Autologous NK Cell Attacks in Patients with Acquired Aplastic Anemia. Blood, 2014, 124, 2939-2939.	1.4	0
98	Relatively Low Sensitivity of CD109(-) Hematopoietic Stem/Progenitor Cells (HSPCs) to TGF-Î ² : A Possible Mechanism Responsible for the Preferential Commitment of Piga Mutant HSPCs in Immune-Mediated Bone Marrow Failure. Blood, 2016, 128, 3911-3911.	1.4	0
99	The Depletion of TGF- \hat{l}^2 Co-Receptor CD109 Induces Erythroid Differentiation of TF-1 Cells: A Model of Preferential Commitment of PIGA-Mutated Hematopoietic Stem Cells in Immune-Mediated Bone Marrow Failure. Blood, 2018, 132, 3874-3874.	1.4	0
100	Escape Hematopoiesis By HLA-B5401-Lacking Hematopoietic Stem Progenitor Cells in Male Patients with Acquired Aplastic Anemia. Blood, 2018, 132, 3855-3855.	1.4	0
101	A GPI-Anchored Protein, CD109, Protects Hematopoietic Progenitor Cells from Erythroid Differentiation Induced By TGF-1². Blood, 2019, 134, 3736-3736.	1.4	0
102	Identification of T-Cell Receptors Specific to Antigens Presented By HLA-B4002 and B5401 in Acquired Aplastic Anemia. Blood, 2019, 134, 3751-3751.	1.4	0
103	Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. Cancers, 2018, 10, .	3.7	О